Responses
Regular and young investigator award abstracts
Clinical trials in progress
328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)
Compose a Response to This Article
Other responses
No responses have been published for this article.
